Massachusetts Financial Services CO Y M Abs Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$11.6 - $17.25 $32,016 - $47,610	2,760 Added 3.47%	82,202 $993,000
Q1 2024 May 14, 2024	SELL	$6.57 - $18.69 $1,149 - $3,270	-175 Reduced 0.22%	79,442 $1.29 Million
Q4 2023 Feb 08, 2024	SELL	$4.88 - $7.42 $12,268 - $18,653	-2,514 Reduced 3.06%	79,617 $542,000
Q3 2023 Nov 08, 2023	BUY	$4.86 - $7.23 $287,716 - $428,023	59,201 Added 258.18%	82,131 $447,000
Q2 2023 Aug 09, 2023	BUY	$5.68 - $10.34 $130,242 - $237,096	22,930 New	22,930 $155,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.